Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease

2009 ◽  
Vol 96 (2) ◽  
pp. 175-184 ◽  
Author(s):  
A. Frilling ◽  
J. Li ◽  
E. Malamutmann ◽  
K.-W. Schmid ◽  
A. Bockisch ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumours ◽  
Hepatic Disease

A Comparison of ree Chromogranin A Assays in Patients with Neuroendocrine Tumours

2014 ◽  
Vol 23 (4) ◽  
pp. 419-424 ◽  
Author(s):  
Lise Brehm Hoej ◽  
Tina Parkner ◽  
Cindy Soendersoe Knudsen ◽  
Henning Grønbaek
Keyword(s):  
Liver Metastases ◽  
Chromogranin A ◽  
Neuroendocrine Tumours ◽  
Single Photon ◽  
Neuroendocrine Tumour ◽  
Photon Emission ◽  
Enzyme Linked Immunosorbent Assay ◽  
Emission Computed Tomography ◽  
Clinical Sensitivity ◽  
Disease Free

Background & Aims: Chromogranin A (CgA) is the most important general tumour marker used in the diagnosis and follow-up of patients with neuroendocrine tumours (NET). Chromogranin A assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients. The aim of this study was to compare the clinical sensitivities of three different CgA assays in NET patients.Methods: We measured CgA level in 42 NET patients (male/female: 23/19, median age: 63 years, range 29- 85 years). Twenty-five patients had liver metastases, eight had local disease, and nine were disease free after surgery. We studied an in-house RIA: RH RIA assay (Rigshospitalet, Copenhagen, Denmark); NEOLISATM (Euro Diagnostica, Malmö, Sweden) and EURIA CgA RIA (Euro Diagnostica, Malmö, Sweden).Results: The RH RIA assay showed a clinical sensitivity of 97%, while the NEOLISA and EURIA assays both showed similar clinical sensitivities of 79%. Patients with liver metastases had significantly higher CgA levels compared to disease free patients by all three assays (P<0.001), but only the RH RIA assay was able to discriminate between patients with liver metastases and with regional disease (P<0.01).Conclusion: Chromogranin A measurements are significantly assay-dependent and caution should be applied in the interpretation of CgA measurement for assessment of NET status. The in-house RH RIA assay was better at predicting NET status than the NEOLISA and EURIA assays.List of abbreviations: CgA: chromogranin A; EURIA: Eurodiagnostica, radioimmunoassay; GFR: glomerular filtration rate; NEOLISA: Eurodiagnostica, enzyme-linked immunosorbent assay; NET: neuroendocrine tumour; PET-CT: positron emission tomography; PPI: proton pump inhibitor; RH RIA: Rigshospitalet, radioimmunoassay ; SPECT-CT: single photon emission computed tomography.

Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases

2008 ◽  
Author(s):  
Kurinchi Selvan Gurusamy ◽  
Rajarajan Ramamoorthy ◽  
Dinesh Sharma ◽  
Brian R Davidson
Keyword(s):  
Liver Resection ◽  
Liver Metastases ◽  
Neuroendocrine Tumours

scholarly journals BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES

2016 ◽  
Vol 29 (3) ◽  
pp. 173-179 ◽  
Author(s):  
Orlando Jorge Martins TORRES ◽  
Márcio Carmona MARQUES ◽  
Fabio Nasser SANTOS ◽  
Igor Correia de FARIAS ◽  
Anelisa Kruschewsky COUTINHO ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Resection ◽  
Liver Metastases ◽  
Multimodal Treatment ◽  
Colorectal Liver Metastases ◽  
Hepatic Disease ◽  
First Line ◽  
Unresectable Disease ◽  
Unresectable Metastases ◽  
Line Chemotherapy

ABSTRACT In the last module of this consensus, controversial topics were discussed. Management of the disease after progression during first line chemotherapy was the first discussion. Next, the benefits of liver resection in the presence of extra-hepatic disease were debated, as soon as, the best sequence of treatment. Conversion chemotherapy in the presence of unresectable liver disease was also discussed in this module. Lastly, the approach to the unresectable disease was also discussed, focusing in the best chemotherapy regimens and hole of chemo-embolization.

scholarly journals Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference

HPB ◽  
2015 ◽  
Vol 17 (1) ◽  
pp. 29-37 ◽  
Author(s):  
Andrew Kennedy ◽  
Lourens Bester ◽  
Riad Salem ◽  
Ricky A. Sharma ◽  
Rowan W. Parks ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumours ◽  
Consensus Conference
Sign in / Sign up

Export Citation Format

Share Document